After a 30-year career in pharmaceutical R&D, John Leonard left his position as Chief Scientific Officer and Senior Vice President of Research and Development at AbbVie in 2013 to affiliate with a private equity firm and participate in various governance roles in the biopharmaceutical industry. Inspired by the opportunity to create curative medicines, he returned to his life’s passion and joined the Intellia team to direct the clinical development of CRISPR/Cas9.
John is among the leading R&D executives who have not only introduced breakthrough medicines, but also guided their development into mega-blockbuster drugs. While serving as the Global Head of Pharmaceutical R&D at Abbott Laboratories, John oversaw the development of numerous novel therapeutics. His ground-breaking work with HIV protease inhibitors Norvir and Kaletra led to new treatment paradigms for AIDS, while his years of work with Humira made it the all-time top-selling drug worldwide. John’s teams were twice recognized with the prestigious Prix Galien Award for excellence in pharmaceutical research.
In addition to serving on the Board of Directors of Intellia, John serves on the Board of Directors of Quintiles (NYSE:Q), Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) and Chimerix (Nasdaq:CMRX). He received his M.D. from the Johns Hopkins University School of Medicine and completed his residency in Internal Medicine at Stanford University School of Medicine followed by a fellowship at the National Institutes of Health.